[HTML][HTML] Role of somatostatin receptor in pancreatic neuroendocrine tumor development, diagnosis, and therapy

Y Hu, Z Ye, F Wang, Y Qin, X Xu, X Yu… - Frontiers in …, 2021 - frontiersin.org
Pancreatic neuroendocrine tumors (pNETs) are rare and part of the diverse family of
neuroendocrine neoplasms (NENs). Somatostatin receptors (SSTRs), which are widely …

Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies

L Lee, T Ito, RT Jensen - Expert review of anticancer therapy, 2018 - Taylor & Francis
Introduction: Recently, there have been a number of advances in imaging pancreatic
neuroendocrine tumors (panNETs), as well as other neuroendocrine tumors (NETs), which …

Somatostatin receptor imaging and theranostics: current practice and future prospects

S Park, AS Parihar, L Bodei, TA Hope… - Journal of Nuclear …, 2021 - Soc Nuclear Med
A new era of precision diagnostics and therapy for patients with neuroendocrine neoplasms
began with the approval of somatostatin receptor (SSTR) radiopharmaceuticals for PET …

Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies

L Lee, T Ito, RT Jensen - Expert review of anticancer therapy, 2019 - Taylor & Francis
Introduction: Recent advances in diagnostic modalities and therapeutic agents have raised
the importance of prognostic factors in predicting overall survival, as well as predictive …

[HTML][HTML] Role of Combined [68Ga]Ga-DOTA-SST Analogues and [18F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review

L Carideo, D Prosperi, F Panzuto, L Magi… - Journal of clinical …, 2019 - mdpi.com
Gastro-entero-pancreatic neuroendocrine neoplasia (GEP-NENs) are rare tumors, but their
frequency is increasing. Neuroendocrine tumors normally express somatostatin (SST) …

[HTML][HTML] Imaging of neuroendocrine tumors of the pancreas

C Dromain, D Déandréis, JY Scoazec, D Goere… - Diagnostic and …, 2016 - Elsevier
Pancreatic neuroendocrine tumors (PNETs) are rare and represent a heterogeneous
disease. PNET can be functioning or non-functioning with different clinical presentations and …

68Ga-DOTATOC PET/MR imaging and radiomic parameters in predicting histopathological prognostic factors in patients with pancreatic neuroendocrine well …

P Mapelli, C Bezzi, D Palumbo, C Canevari… - European Journal of …, 2022 - Springer
Purpose To explore the role of fully hybrid 68Ga-DOTATOC PET/MR imaging and radiomic
parameters in predicting histopathological prognostic factors in patients with pancreatic …

[HTML][HTML] Neuroendocrine tumors and peptide receptor radionuclide therapy: when is the right time?

TA Hope, M Pavel, EK Bergsland - Journal of Clinical Oncology, 2022 - ncbi.nlm.nih.gov
Since its approval in 2018 by the US Food and Drug Administration, peptide receptor
radionuclide therapy (PRRT) has become a mainstay in the treatment of neuroendocrine …

[HTML][HTML] Radiomics-Based Texture Analysis of 68Ga-DOTATATE Positron Emission Tomography and Computed Tomography Images as a Prognostic Biomarker in Adults With …

C Atkinson, B Ganeshan, R Endozo, S Wan… - Frontiers in …, 2021 - frontiersin.org
Purpose Neuroendocrine tumors (NET) are rare cancers with variable behavior. A better
understanding of prognosis would aid individualized management. The aim of this …

[HTML][HTML] Imaging of pancreatic neuroendocrine neoplasms

G Chiti, G Grazzini, D Cozzi, G Danti… - International journal of …, 2021 - mdpi.com
Pancreatic neuroendocrine neoplasms (panNENs) represent the second most common
pancreatic tumors. They are a heterogeneous group of neoplasms with varying clinical …